文献速递乳腺外科

吲哚菁绿荧光成像在乳腺癌前哨淋巴结定位中的非劣效性试验

Sentinel Lymph Node Mapping in Breast Cancer Patients Through Fluorescent Imaging Using Indocyanine Green: The INFLUENCE Trial.
PubMed 文献 · Ann Surg · 2022-07-27

INFLUENCE 试验纳入 102 例临床淋巴结阴性早期浸润性乳腺癌患者,比较 ICG 荧光成像与 99mTc-纳米胶体定位前哨淋巴结的检出率。结果显示 ICG 荧光检出率为 96.1%,99mTc-纳米胶体为 86.4%,两者对病理阳性淋巴结检出率均为 86.7%。ICG 荧光成像安全有效,可作为 99mTc-纳米胶体的替代方法。

要点

  • ICG 荧光前哨淋巴结检出率 96.1%,高于 99mTc-纳米胶体的 86.4%。
  • 两者对病理阳性前哨淋巴结检出率均为 86.7%。
  • ICG 荧光成像未增加检出时间,未见不良事件。

核心结论

  • ICG 荧光成像的前哨淋巴结检出率高于 99mTc-纳米胶体,对病理阳性前哨淋巴结检出率两者相等。

研究设计与样本

  • 非劣效性试验,纳入 102 例连续入组的临床淋巴结阴性早期浸润性乳腺癌患者,计划行保乳手术和前哨淋巴结活检,研究时间为 2020 年 8 月至 2021 年 6 月。

主要发现

  • 共分析 103 例次前哨淋巴结活检,ICG 荧光检出率为 96.1%(95%CI=90.4%-98.9%),99mTc-纳米胶体为 86.4%(95%CI=78.3%-92.4%)。
  • 病理阳性淋巴结检出率 ICG 和 99mTc-纳米胶体均为 86.7%(95%CI=59.5%-98.3%)。
  • 中位切除淋巴结数为 2 枚,ICG 荧光成像未增加检出时间,未观察到不良事件。

关键数值与推荐

  • 检出率定义为至少检出 1 枚前哨淋巴结的患者比例。
  • 术前一天或当天早晨注射 99mTc-纳米胶体,先以 ICG 荧光成像行前哨淋巴结活检,离体淋巴结用伽马探针检测 99mTc 摄取,并检查腋窝残留 99mTc 活性。

临床怎么用

  • ICG 荧光成像可作为早期乳腺癌前哨淋巴结活检中 99mTc-纳米胶体的安全有效替代方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to compare the (sentinel) lymph node detection rate of indocyanine green (ICG)-fluorescent imaging versus standard-of-care 99m Tc-nanocoilloid for sentinel lymph node (SLN)-mapping. BACKGROUND: The current gold standard for axillary staging in patients with breast cancer is sentinel lymph node biopsy (SLNB) using radio-guided surgery using radioisotope technetium ( 99m Tc), sometimes combined with blue dye. A promising alternative is fluorescent imaging using ICG. METHODS: In this noninferiority trial, we enrolled 102 consecutive patients with invasive early-stage, clinically node-negative breast cancer. Patients were planned for breast conserving surgery and SLNB between August 2020 and June 2021. The day or morning before surgery, patients were injected with 99m Tc-nanocolloid. In each patient, SLNB was first performed using ICG-fluorescent imaging, after which excised lymph nodes were tested with the gamma-probe for 99m Tc-uptake ex vivo, and the axilla was checked for residual 99m Tc-activity. The detection rate was defined as the proportion of patients in whom at least 1 (S)LN was detected with either tracer. RESULTS: In total, 103 SLNBs were analyzed. The detection rate of ICG-fluorescence was 96.1% [95% confidence interval (95% CI)=90.4%-98.9%] versus 86.4% (95% CI=78.3%-92.4%) for 99m Tc-nanocoilloid. The detection rate for pathological lymph nodes was 86.7% (95% CI=59.5%-98.3%) for both ICG and 99m Tc-nanocoilloid. A median of 2 lymph nodes were removed. ICG-fluorescent imaging did not increase detection time. No adverse events were observed. CONCLUSIONS: ICG-fluorescence showed a higher (S)LN detection rate than 99m Tc-nanocoilloid, and equal detection rate for pathological (S)LNs. ICG-fluorescence may be used as a safe and effective alternative to 99m Tc-nanocoilloid for SLNB in patients with early-stage breast cancer.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Bargon CA, Huibers A, Young-Afat DA, et al. Sentinel Lymph Node Mapping in Breast Cancer Patients Through Fluorescent Imaging Using Indocyanine Green: The INFLUENCE Trial. Ann Surg. 2022. PMID: 35894448. doi:10.1097/SLA.0000000000005633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。